WP1: During the project, the new Q-, NADH and PB-Modules ― supported by the new architecture of the upgraded DatLab software ― have been developed and integrated. Additionally, we have successfully partnered with Key Opinion Leaders, whom we trained either on-site or virtually, for testing the Q- and PB-Modules. Feedback from the KOLs led to an additional photobiology light source (PBLS) and adjustment of the PB-Module. Furthermore, features of the new DatLab 8 software implemented by our subcontractor H-Tech were intensely tested and substrate-uncoupler-inhibitor-titration (SUIT) protocols were integrated.
WP2: Optimal measurement conditions were determined for using the Q-, NADH- and PB-Modules with a variety of biological samples. Simultaneously test programmes of the beta version of DatLab 8 including the new modules were conducted and improvements applied. New SUIT protocols were developed for general, pre-clinical, and algal biotechnology applications. A focus was also given to internal and external quality control measures, an important factor in the development of the NextGen-O2k instrument and relevant protocols.
WP3: In year one of the project, we aimed to improve the reproducibility of experimental assays and support customers with new developments. Therefore, we created an SOP for the new Q-Module, 6 new manuals and O2k-Videosupport clips for the Q-Module, DatLab7.4 mitochondrial preparations, and TPP+ and ion selective electrodes ISE. In the second year, we generated SOPs for the NextGen-O2k which were included in manuals and tutorial videos. These manuals and video clips, along with webinars, provide step-by step instructions, support, and information for using the NextGen-O2k.
WP4: As a cornerstone of our IP strategy, we successfully registered “NextGen-O2k”, “DatLab”, “High-Resolution Respirometry” and “O2k” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we increased our distributor engagement, helping us learning more about the market and customer needs. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications in collaboration with Key Opinion Leaders, which led to a publication. Although no certification for ISO is planned, several management documents have been created and implemented.
WP5: At the beginning of the project, we created a website to disseminate the results and also created a customer-friendly product website. For further strengthening our brand recognition, a communication strategy was put in place to bring an updated corporate identity with a new look to marketing materials and increased social media presence. Marketing materials, such as the NextGen-O2k folder and booth, were finalized and updated existing materials according to the latest corporate design. In addition to our print and digital presence, the Oroboros Team attended international conferences and hosted O2k-Workshops. Due to the COVID-19 pandemic, conference participation was restricted to virtual events and the concept of personalized individual training of the customers was implemented. KOLs, with whom we worked closely on prototype testing, were our first group to receive training in this format. To bring awareness to relevant scientific publications in the field, O2k-briefs summarizing key work were published regularly. Furthermore, an open access peer-reviewed journal, Bioenergetics Communications, was initiated. www.bioenergetics-communications.org/ linked to the MitoFit Preprints server. Several scientific and methodological papers were published by our group or in collaboration with KOLs.
